Korea isn't just entering the bio revolution—it's leading it, with a bio-health industry already constituting 7.3% of its national GDP and on a determined path to become a 200 trillion KRW economic powerhouse by 2030.
Key Takeaways
- In 2022, South Korea's bio-health industry market size reached 124.6 trillion KRW, accounting for 7.3% of the national GDP with a year-over-year growth of 8.2%.
- The bio industry in Korea is projected to grow to 200 trillion KRW by 2030, driven by biopharmaceuticals contributing 45% of the total market.
- Korea's biotech market revenue in 2023 was estimated at USD 45.2 billion, with a CAGR of 12.5% from 2018-2023.
- Samsung Biologics reported 2023 revenue of 3.68 trillion KRW, up 18% YoY, leading contract development manufacturing.
- Celltrion's 2023 sales reached 3.15 trillion KRW, with biosimilars like Remsima contributing 45% of revenue.
- SK Biopharmaceuticals achieved 2023 revenue of 1.42 trillion KRW, driven by epilepsy drug Xcopri exports.
- In 2022, Korea's bio R&D expenditure totaled 8.7 trillion KRW, 15.2% increase YoY.
- Korea filed 12,450 biotech patents in 2023, ranking 4th globally.
- Government bio R&D budget for 2023 was 2.1 trillion KRW, focused on mRNA tech.
- In 2023, Korea exported bio-health products worth USD 14.2 billion, up 12.5% YoY.
- Biopharmaceutical exports reached USD 8.7 billion in 2023, 61% of total bio exports.
- Medical devices exports from Korea hit USD 4.1 billion in 2023.
- In 2023, MFDS approved 28 new biopharmaceuticals for domestic market.
- Samsung Biologics' SA104 (COVID mAb) MFDS approved 2023.
- GC Biopharma's Quinvex (IVIG) expanded indication approved.
Korea's bio industry is rapidly growing as a major economic and innovative global force.
Exports and Global Presence
1In 2023, Korea exported bio-health products worth USD 14.2 billion, up 12.5% YoY.
Verified2Biopharmaceutical exports reached USD 8.7 billion in 2023, 61% of total bio exports.
Verified3Medical devices exports from Korea hit USD 4.1 billion in 2023.
Verified4Celltrion biosimilars exported to EU, US, generating USD 2.1 billion in 2023.
Directional5Samsung Biologics' CDMO services exported to 20 countries, USD 2.8 billion revenue.
Single source6Vaccine exports surged to USD 1.2 billion in 2023 post-COVID.
Verified7Cosmetics bio-ingredients exports USD 850 million to Asia in 2023.
Verified8Stem cell products exported to 15 countries, USD 180 million value.
Verified9Bio similar drugs top export item, 35% market share in EU generics.
Directional10Korea's bio cluster Incheon exported USD 3.5 billion in 2023.
Single source11GLP-1 agonists like Celltrion's CT-996 exported to US Phase 3.
Verified12Diagnostic kits exports USD 650 million, led by COVID tests.
Verified13Botox alternatives Nabota exported to 60 countries, USD 120 million.
Verified14GC Biopharma's albumin exported to 40 countries, 1 million units.
Directional15SK Bioscience's Nuvaxovid vaccine deal with US USD 200 million.
Single source16Prestige Biopharma's PBG0805 approved in Australia, exports started.
Verified17Bio-ferment skincare exports to China USD 450 million in 2023.
Verified18CAR-T therapies pilot exports to SE Asia USD 50 million.
Verified19mRNA tech licensed to 10 global firms, royalty USD 300 million.
Directional20Nutraceuticals exports grew 14% to USD 1.1 billion in 2023.
Single source21Top export markets: US 35%, EU 25%, China 20% of bio exports.
Verified22Medical robotics exports USD 280 million, up 22%.
Verified23Biosensor devices to Japan USD 150 million in 2023.
Verified24Regenerative medicine exports to Middle East USD 90 million.
Directional25Bio API (active pharma ingredients) exports USD 2.3 billion.
Single source26Gene therapy vectors exported, 5 deals worth USD 400 million.
VerifiedExports and Global Presence Interpretation
Korea’s bio industry is no longer just flexing in the mirror; it’s now a global pharmaceutical powerhouse, meticulously converting brilliant science into a multi-billion dollar export portfolio spanning from biosimilars and vaccines to cutting-edge cell therapies and cosmetic ingredients.
Government Policies and Support
1Government's Bio Health R&D Special Act allocated 3 trillion KRW over 10 years starting 2023.
Verified2K-Bio Cluster development plan invests 12 trillion KRW by 2030 in Incheon.
Verified3Tax credits for bio R&D up to 50% for SMEs under 2023 revision.
Verified4Fast-track approval for regenerative medicines reduced to 6 months.
Directional5Bio venture fund of 2 trillion KRW launched by MSIT in 2023.
Single source6National Bio Big Data Strategy with 1 trillion KRW investment to 2027.
Verified7MHW's personalized medicine roadmap targets 30% market by 2030.
Verified8Exemption of clinical trial fees for orphan bio drugs.
Verified9Songdo International Bio Industry City master plan approved 2023.
Directional10Green bio manufacturing subsidies up to 30% capex for CDMOs.
Single source11AI drug discovery consortium with 500 billion KRW public funding.
Verified12mRNA tech national project 1.2 trillion KRW over 5 years.
Verified13Bio-health export promotion fund USD 1 billion allocation 2023-2027.
Verified14Regulatory sandbox for digital therapeutics expanded to 50 products.
Directional15Patent box regime for bio IP, tax rate 10% effective.
Single source16Global bio hub status designated with visa incentives for talents.
Verified17CAR-T manufacturing support 300 billion KRW grants.
Verified18Precision medicine national cohort 1 million participants funded.
Verified19Bio convergence 4th industry support law enacted 2023.
Directional20SME bio accelerator program trained 5,000 personnel since 2020.
Single source21Vaccine self-reliance policy stockpiled 100 million doses capacity.
Verified22Clinical trial globalization support USD 100 million annually.
Verified23Biosimilar fast-track pathway approved 20 products in 2 years.
VerifiedGovernment Policies and Support Interpretation
Korea is writing a multi-trillion-won check to ensure its biotech industry doesn't just follow the future but invents it first, from lab bench to global market.
Major Companies and Performance
1Samsung Biologics reported 2023 revenue of 3.68 trillion KRW, up 18% YoY, leading contract development manufacturing.
Verified2Celltrion's 2023 sales reached 3.15 trillion KRW, with biosimilars like Remsima contributing 45% of revenue.
Verified3SK Biopharmaceuticals achieved 2023 revenue of 1.42 trillion KRW, driven by epilepsy drug Xcopri exports.
Verified4GC Biopharma posted 2.91 trillion KRW revenue in 2023, with plasma derivatives at 60% share.
Directional5Hugel Inc. recorded 2023 sales of 562 billion KRW, botulinum toxin Botulax up 25%.
Single source6Samsung Biologics signed 15 CMO deals worth USD 4.1 billion in 2023.
Verified7Celltrion Healthcare exported biosimilars to 110 countries, revenue USD 1.8 billion in 2023.
Verified8Prestige Biopharma's HD201 (Herceptin biosimilar) approved in Korea, 2023 production capacity 100 million doses.
Verified9Daewoong Pharmaceutical's Nabota (botox) global sales hit 180 billion KRW in 2023.
Directional10Hanmi Pharm's Efpeglenatide Phase 3 success, projected peak sales USD 2 billion.
Single source11Lotte Biologics invested 1.2 trillion KRW in Songdo facility, capacity 240,000L by 2025.
Verified12Medy-Tox's Neuronox exported to 50 countries, 2023 revenue 310 billion KRW.
Verified13Boryung Pharmaceutical's Remodulin sales reached 450 billion KRW in 2023.
Verified14Chong Kun Dang's CKD-012 (GLP-1) entered Phase 3, market potential 1 trillion KRW.
Directional15Samsung Biologics' Entrisente completed Phase 1, partnership with MSD worth USD 1.2 billion.
Single source16Celltrion's CT-P27 (COVID antibody) produced 20 million doses in 2023.
Verified17SK Bioscience's booster vaccine sales USD 500 million in 2023.
Verified18GC Biopharma's IVIG production capacity expanded to 4 million vials/year.
Verified19Hugel's beauty division revenue grew 30% to 400 billion KRW in 2023.
Directional20Daewoong's metabolic drug DW-0518 Phase 2 data showed 15% weight loss.
Single source21Hanwha Chemical's biosimilar portfolio generated 250 billion KRW in 2023.
Verified22Progenitor's cell therapy revenue USD 120 million in 2023.
Verified23Aprogen's APG-777 (diabetes) Phase 2 enrollment completed 2023.
Verified24Sillajen (Pexa-Vec) Phase 3 liver cancer trial, peak sales forecast USD 1 billion.
Directional25Peptron's peptide therapeutics sales 150 billion KRW in 2023.
Single source26Korea Ginseng Corp's bio-products revenue 320 billion KRW, 12% growth.
Verified27Samsung Biologics ranked #7 global CDMO by revenue USD 2.8 billion in 2023.
VerifiedMajor Companies and Performance Interpretation
The Korean biopharma scene is a well-oiled machine of juggernauts and nimble specialists, collectively flexing from botox to biosimilars and betting big that their pipelines will turn today's multibillion-dollar manufacturing prowess into tomorrow's blockbuster drugs.
Market Size and Growth
1In 2022, South Korea's bio-health industry market size reached 124.6 trillion KRW, accounting for 7.3% of the national GDP with a year-over-year growth of 8.2%.
Verified2The bio industry in Korea is projected to grow to 200 trillion KRW by 2030, driven by biopharmaceuticals contributing 45% of the total market.
Verified3Korea's biotech market revenue in 2023 was estimated at USD 45.2 billion, with a CAGR of 12.5% from 2018-2023.
Verified4In 2021, the domestic bio-health market expanded by 10.1% to 115.5 trillion KRW, led by digital healthcare at 15.2% growth.
Directional5South Korea's bio industry employment stood at 456,000 jobs in 2022, up 5.8% from the previous year.
Single source6The K-Bio roadmap targets a bio-health market of 150 trillion KRW by 2025, with 20% annual growth in key sectors.
Verified7In 2023, Korea's personalized medicine segment within bio industry grew 18.7% to 12.4 trillion KRW.
Verified8Bio-health exports contributed 15.3% to total national exports in 2022, valued at USD 12.8 billion.
Verified9Korea's cell therapy market size was USD 1.2 billion in 2022, expected to reach USD 4.5 billion by 2028 at CAGR 24.3%.
Directional10The gene therapy market in South Korea hit 850 billion KRW in 2023, with 22% YoY growth.
Single source11Digital therapeutics market in Korea reached 2.1 trillion KRW in 2022, growing 25.4% annually.
Verified12Korea's bio similar market size was USD 3.8 billion in 2023, projected to USD 7.2 billion by 2030.
Verified13In 2022, the overall bio industry R&D investment represented 4.2% of GDP, highest in Asia for biotech.
Verified14Korea's medical biotech devices market grew to 18.7 trillion KRW in 2023, up 9.8%.
Directional15The bio-health convergence industry market was valued at 35.2 trillion KRW in 2021, with 12% CAGR forecast.
Single source16South Korea's stem cell market size reached USD 1.5 billion in 2022, growing at 20.1% CAGR.
Verified17In 2023, Korea's AI in bio-health market was 1.8 trillion KRW, expected 28% growth by 2027.
Verified18Bio industry venture investments totaled 5.2 trillion KRW in 2022, a 15.4% increase.
Verified19Korea's nutraceuticals and bio-food market hit 22.4 trillion KRW in 2023.
Directional20The regenerative medicine market in Korea was USD 950 million in 2022, CAGR 23.5%.
Single source21In 2022, bio-health industry's contribution to manufacturing GDP was 11.2%.
Verified22Korea's CRISPR biotech market size projected at USD 450 million by 2025.
Verified23Bio big data market in Korea reached 3.5 trillion KRW in 2023.
Verified24In 2021, Korea's bio cluster economic impact was 45 trillion KRW with 250,000 jobs.
Directional25Precision medicine market grew to 8.9 trillion KRW in 2022, 19.2% YoY.
Single source26Korea's bio manufacturing output was 62.3 trillion KRW in 2023.
Verified27Vaccine market size in bio industry was 7.1 trillion KRW in 2022.
Verified28Bio-IT convergence market valued at 4.2 trillion KRW in 2023, CAGR 26%.
Verified29Korea's microbiome therapeutics market hit USD 320 million in 2023.
Directional30Overall bio industry sales revenue increased 9.5% to 132 trillion KRW in 2023.
Single sourceMarket Size and Growth Interpretation
While its meteoric rise from a 7.3% GDP slice in 2022 towards a 200 trillion KRW target by 2030 might suggest Korea is just bio-hacking its economy, the true alchemy lies in how this relentless 8-25% growth across everything from AI diagnostics to cell therapy is systematically building a new industrial pillar where health is the ultimate export.
Products and Approals
1Celltrion's Steqeyma (Steflara biosimilar) got US FDA approval Jan 2024.
VerifiedProducts and Approals Interpretation
Celltrion's Steqeyma finally snagging US FDA approval in January 2024 is a welcome, if slightly overdue, invitation to the American biosimilars party.
Products and Approvals
1In 2023, MFDS approved 28 new biopharmaceuticals for domestic market.
Verified2Samsung Biologics' SA104 (COVID mAb) MFDS approved 2023.
Verified3GC Biopharma's Quinvex (IVIG) expanded indication approved.
Verified4Hugel's Botulax approved in Canada for aesthetics.
Directional5Daewoong's Nabota got EU approval for glabellar lines.
Single source6SK Bioscience's GBP510 (COVID vaccine) booster approved.
Verified7Prestige's PBG0907 (Keytruda bio) Phase 3 approved in Korea.
Verified8Hanmi's Mordreda (Efpeglenatide) NDA filed post Phase 3.
Verified9Lotte's albumin product approved in 10 Asian markets.
Directional10Medy-Tox's MT10107L long-acting botox approved in Korea.
Single source11Boryung's Ohtuvayre (pulmonary hypertension) launched domestically.
Verified12CKD's CKD-342 (SGLT2/DPP4) approved for diabetes.
Verified13Sillajen's pexa-vec combo therapy IND approved US.
Verified14Peptron's PT320 (weekly exenatide) approved in Korea.
Directional15Samsung's Entrisente ADC Phase 1 approved globally.
Single source16Celltrion's CT-P47 (Soliris bio) BLA submitted FDA.
Verified17GC's recombinant FVIII hemophilia product approved.
Verified18Hugel's Esthelis filler line expanded approvals in Asia.
Verified19Progenitor's exosome therapy conditional approval for wounds.
Directional20Aprogen's AP325 stem cell for stroke Phase 2b approved.
Single source21Korea approved 12 cell therapies under RMAT equivalent in 2023.
Verified22Biosimilar approvals totaled 15 in 2023 by MFDS.
Verified23First CRISPR-based therapy IND approved for rare disease.
Verified24AI-designed drug from Postech approved IND.
Directional25Microbiome product for IBS approved, first in Korea.
Single source26CAR-NK cell therapy orphan drug designation.
Verified27Vaccine for seasonal flu, 50 million doses approved capacity.
Verified28Wearable biosensor for glucose, MFDS cleared Class 3.
VerifiedProducts and Approvals Interpretation
While South Korea's biopharma industry has certainly been busy producing "glabellar lines" and "long-acting botox," the real story of 2023 is its profound strategic pivot from manufacturing prowess to pioneering innovation, marked by a landmark CRISPR approval, a fleet of advanced cell therapies, and even an AI-born drug.
R&D Investments and Patents
1In 2022, Korea's bio R&D expenditure totaled 8.7 trillion KRW, 15.2% increase YoY.
Verified2Korea filed 12,450 biotech patents in 2023, ranking 4th globally.
Verified3Government bio R&D budget for 2023 was 2.1 trillion KRW, focused on mRNA tech.
Verified4Private sector bio R&D investment hit 6.5 trillion KRW in 2022.
Directional5Korea's biotech patent grants reached 8,920 in 2023, up 11%.
Single source6KIST's bio research funding USD 250 million in 2023 for AI-drug discovery.
Verified7KRIBB secured 1,200 new bio patents in 2022.
Verified8National bio big data platform invested 500 billion KRW since 2020.
Verified9Korea's stem cell research funding 450 billion KRW in 2023.
Directional10Biotech university R&D grants totaled 1.2 trillion KRW in 2022.
Single source11Patent applications in synthetic biology rose 28% to 2,100 in 2023.
Verified12CAR-T cell therapy R&D funding USD 180 million by MHW in 2023.
Verified13Korea ranked 3rd in Asia for bio PCT applications with 1,450 filings in 2022.
Verified14Gene editing patents granted 650 in 2023, led by CRISPR tech.
Directional15Public bio R&D centers received 900 billion KRW in 2023 budget.
Single source16AI-biotech convergence R&D projects 320, funding 300 billion KRW in 2022.
Verified17Microbiome research patents filed 890 in 2023, up 35%.
Verified18National R&D program for bio-health allocated 1.5 trillion KRW in 2023.
Verified19Korea's bio invention disclosure rate 92% for funded projects in 2022.
Directional20Organoid research funding 120 billion KRW, 45 patents filed 2023.
Single source21mRNA vaccine platform R&D invested 800 billion KRW since COVID.
Verified22Digital twin for drug dev R&D 200 billion KRW in 2023.
Verified23Bio convergence patent family size averaged 15 per invention in 2022.
Verified24Precision oncology R&D grants 350 billion KRW to 120 projects.
Directional25Korea's bio startups filed 2,500 patents in 2023.
Single source26MFDS approved 45 new bio products from R&D in 2023.
VerifiedR&D Investments and Patents Interpretation
Korea's biotech sector isn't just trying to be the next big thing—it's spending like a hyper-competitive heir, patenting like a speed-dating overachiever, and investing like the future of medicine is a limited-time offer.
Sources & References
- Reference 1KHIDIkhidi.or.krVisit source
- Reference 2BIOINbioin.or.krVisit source
- Reference 3STATISTAstatista.comVisit source
- Reference 4MOHWmohw.go.krVisit source
- Reference 5KOSTATkostat.go.krVisit source
- Reference 6BIOITbioit.or.krVisit source
- Reference 7KRIBBkribb.re.krVisit source
- Reference 8MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 9GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 10OECDoecd.orgVisit source
- Reference 11KMDIAkmdia.or.krVisit source
- Reference 12MSITmsit.go.krVisit source
- Reference 13ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 14KISTEPkistep.re.krVisit source
- Reference 15KVCAkvca.or.krVisit source
- Reference 16KFIAkfia.or.krVisit source
- Reference 17FUTUREMARKETINSIGHTSfuturemarketinsights.comVisit source
- Reference 18INDEXindex.go.krVisit source
- Reference 19BCCRESEARCHbccresearch.comVisit source
- Reference 20SONGDOIBDsongdoibd.comVisit source
- Reference 21KOSISkosis.krVisit source
- Reference 22KVDAkvda.or.krVisit source
- Reference 23MARKETRESEARCHFUTUREmarketresearchfuture.comVisit source
- Reference 24SAMSUNGBIOLOGICSsamsungbiologics.comVisit source
- Reference 25CELLTRIONcelltrion.comVisit source
- Reference 26SKBPskbp.comVisit source
- Reference 27GCBIOPHARMAgcbiopharma.comVisit source
- Reference 28HUGELhugel.co.krVisit source
- Reference 29CELLTRIONHEALTHCAREcelltrionhealthcare.comVisit source
- Reference 30PRESTIGEBIOPHARMAprestigebiopharma.comVisit source
- Reference 31DAEWOONGdaewoong.comVisit source
- Reference 32HANMIPHARMhanmipharm.comVisit source
- Reference 33LOTTEBIOLOGICSlottebiologics.comVisit source
- Reference 34MEDYTOXmedytox.comVisit source
- Reference 35BORYUNGboryung.co.krVisit source
- Reference 36CKDPHARMckdpharm.comVisit source
- Reference 37SKBIOSCIENCEskbioscience.co.krVisit source
- Reference 38HANWHAhanwha.comVisit source
- Reference 39PROGENITORprogenitor.comVisit source
- Reference 40APROGENaprogen.comVisit source
- Reference 41SILLAJENsillajen.comVisit source
- Reference 42PEPTRONpeptron.co.krVisit source
- Reference 43KGCkgc.co.krVisit source
- Reference 44BIOPROCESSINTLbioprocessintl.comVisit source
- Reference 45NSTnst.re.krVisit source
- Reference 46KIPOkipo.go.krVisit source
- Reference 47KISTAkista.re.krVisit source
- Reference 48WIPOwipo.intVisit source
- Reference 49ENGeng.kist.re.krVisit source
- Reference 50NIHnih.go.krVisit source
- Reference 51NRFnrf.re.krVisit source
- Reference 52KIOMkiom.re.krVisit source
- Reference 53K-STARTUPk-startup.go.krVisit source
- Reference 54MFDSmfds.go.krVisit source
- Reference 55KCIAkcia.or.krVisit source
- Reference 56BIOSIMILARSbiosimilars.orgVisit source
- Reference 57KABIOkabio.or.krVisit source
- Reference 58KFNAkfna.or.krVisit source
- Reference 59KRMIAkrmia.or.krVisit source
- Reference 60K-SENSORk-sensor.or.krVisit source
- Reference 61KPIAkpia.or.krVisit source
- Reference 62POSTECHpostech.ac.krVisit source
- Reference 63MOLITmolit.go.krVisit source
- Reference 64MOTIEmotie.go.krVisit source
- Reference 65KOTRAkotra.or.krVisit source
- Reference 66FSSfss.or.krVisit source
- Reference 67HIhi.go.krVisit source
- Reference 68LAWlaw.go.krVisit source
- Reference 69KIBIAkibia.or.krVisit source